Please login to the form below

Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... NICE agreed last year that Halaven should be made

Latest news

NICE backs Eisai's Halaven for breast cancer

NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug. ... Halaven is one of Eisai's key growth products, accounting for 18.6bn yen ($181m) in sales in the first half of this fiscal year
Lilly closes on first approval for sarcoma drug Lartruvo

If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Eisai gets green light for Lenvima in kidney cancer

Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Oncology directions

Halaven (eribulin).
Disappointment for pharma with new Cancer Drugs Fund list

While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who are
Country report: The healthcare market in Japan

The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Head of Partnerships - Competitive - London: Competitive Salary Offered

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Midweight Brand Planner: Up to £50, 000

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Investing in our People: As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Body image and mental health: The psoriasis connection: As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
It’s not the end of the world, is it?: Industry change isn’t always gradual – it can be apocalyptic...